GERON CORP
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
GERN | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 919 EAST HILLSDALE BOULEVARD, 94404 FOSTER CITY
- Website:
- https://www.geron.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for hematologic malignancies. The company's core strategy is centered on its first-in-class telomerase inhibitor, RYTELO™ (imetelstat), a therapeutic designed to treat blood cancers. Building on pioneering science related to telomerase, Geron aims to alter the course of these diseases for patients. The company's lead product is approved in the United States for the treatment of specific myeloid hematologic malignancies, marking its transition from a clinical-stage to a commercial entity.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all GERON CORP filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GERON CORP
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GERON CORP via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
